{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:36:00Z","timestamp":1793730960138,"version":"4.6.1"},"reference-count":126,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":48,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2024ZD0520600"],"award-info":[{"award-number":["2024ZD0520600"]}]},{"name":"Beijing Hospitals Authority\u2019s Ascent Plan","award":["DFL20241104"],"award-info":[{"award-number":["DFL20241104"]}]},{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"crossref","award":["Y-2022HER2AZQN-0080"],"award-info":[{"award-number":["Y-2022HER2AZQN-0080"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-026-01804-8","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T11:23:17Z","timestamp":1778239397000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Chinese guidelines for HER2-targeted therapy in gastric and gastroesophageal junction adenocarcinoma (2025 Edition)"],"prefix":"10.1186","volume":"19","author":[{"given":"Xiaotian","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yakun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muyan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenghua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqi","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangshan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujuan","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie\u2019er","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaozhen","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianshu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlong","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruihua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"issue":"21","key":"1804_CR1","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1001\/jama.2023.19918","volume":"330","author":"J Xu","year":"2023","unstructured":"Xu J, Jiang H, Pan Y, Gu K, Cang S, Han L, et al. Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial. JAMA. 2023;330(21):2064\u201374.","journal-title":"JAMA"},{"key":"1804_CR2","doi-asserted-by":"publisher","first-page":"S899","DOI":"10.1016\/j.annonc.2020.08.1928","volume":"31","author":"K Yamaguchi","year":"2020","unstructured":"Yamaguchi K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, et al. 1422MO trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-low, advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: results of the exploratory cohorts in the phase II, multicenter, open-label DESTINY-Gastric01 study. Ann Oncol. 2020;31:S899\u2013900.","journal-title":"Ann Oncol"},{"issue":"11","key":"1804_CR3","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1002\/cac2.12214","volume":"41","author":"Z Peng","year":"2021","unstructured":"Peng Z, Liu T, Wei J, Wang A, He Y, Yang L, et al. Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study. Cancer Commun (Lond). 2021;41(11):1173\u201382.","journal-title":"Cancer Commun (Lond)"},{"issue":"25","key":"1804_CR4","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","volume":"382","author":"K Shitara","year":"2020","unstructured":"Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382(25):2419\u201330.","journal-title":"N Engl J Med"},{"issue":"4","key":"1804_CR5","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","volume":"64","author":"G Guyatt","year":"2011","unstructured":"Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383\u201394.","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"1804_CR6","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","volume":"64","author":"H Balshem","year":"2011","unstructured":"Balshem H, Helfand M, Sch\u00fcnemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401\u20136.","journal-title":"J Clin Epidemiol"},{"issue":"7","key":"1804_CR7","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.jclinepi.2013.02.003","volume":"66","author":"JC Andrews","year":"2013","unstructured":"Andrews JC, Sch\u00fcnemann HJ, Oxman AD, Pottie K, Meerpohl JJ, Coello PA, et al. GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation\u2019s direction and strength. J Clin Epidemiol. 2013;66(7):726\u201335.","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"1804_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101582","volume":"8","author":"I Nakayama","year":"2023","unstructured":"Nakayama I, Takahari D, Chin K, Wakatsuki T, Takamatsu M, Yamamoto N, et al. Incidence, clinicopathological features, and clinical outcomes of low HER2 expressed, inoperable, advanced, or recurrent gastric\/gastroesophageal junction adenocarcinoma. ESMO Open. 2023;8(4):101582.","journal-title":"ESMO Open"},{"key":"1804_CR9","doi-asserted-by":"publisher","first-page":"S869","DOI":"10.1016\/j.annonc.2023.09.1463","volume":"34","author":"CK Lee","year":"2023","unstructured":"Lee CK, Park S, Che J, Kwon WS, Rha SY. 1551P clinicopathologic characteristics and genomic profiling of HER2-low advanced gastric cancer. Ann Oncol. 2023;34:S869.","journal-title":"Ann Oncol"},{"issue":"4_suppl","key":"1804_CR10","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1200\/JCO.2023.41.4_suppl.326","volume":"41","author":"MF Mulcahy","year":"2023","unstructured":"Mulcahy MF, Nimeiri H, Rahma OE, Wills J, Rosario KD, Lien J, et al. Real-world outcome analysis of patients with advanced gastric and gastroesophageal adenocarcinoma with HER2-low expression treated with first-line therapy. J Clin Oncol. 2023;41(4_suppl):326.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1804_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103679","volume":"9","author":"K Shimozaki","year":"2024","unstructured":"Shimozaki K, Fukuoka S, Ooki A, Yamaguchi K. HER2-low gastric cancer: is the subgroup targetable? ESMO Open. 2024;9(9):103679.","journal-title":"ESMO Open"},{"issue":"4","key":"1804_CR12","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1200\/JCO.22.00575","volume":"41","author":"K Yamaguchi","year":"2023","unstructured":"Yamaguchi K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, et al. Trastuzumab deruxtecan in anti-human epidermal growth factor receptor 2 treatment-naive patients with human epidermal growth factor receptor 2-low gastric or gastroesophageal junction adenocarcinoma: exploratory cohort results in a phase ii trial. J Clin Oncol. 2023;41(4):816\u201325.","journal-title":"J Clin Oncol"},{"issue":"9742","key":"1804_CR13","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687\u201397.","journal-title":"Lancet"},{"issue":"2","key":"1804_CR14","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/annonc\/mdi064","volume":"16","author":"M Tanner","year":"2005","unstructured":"Tanner M, Hollm\u00e9n M, Junttila TT, Kapanen AI, Tommola S, Soini Y, et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol. 2005;16(2):273\u20138.","journal-title":"Ann Oncol"},{"issue":"9","key":"1804_CR15","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1093\/annonc\/mdn169","volume":"19","author":"C Gravalos","year":"2008","unstructured":"Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19(9):1523\u20139.","journal-title":"Ann Oncol"},{"issue":"3","key":"1804_CR16","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s10120-014-0402-y","volume":"18","author":"E Van Cutsem","year":"2015","unstructured":"Van Cutsem E, Bang YJ, Feng-Yi F, Xu JM, Lee KW, Jiao SC, et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer. 2015;18(3):476\u201384.","journal-title":"Gastric Cancer"},{"issue":"9","key":"1804_CR17","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1093\/annonc\/mdt232","volume":"24","author":"WQ Sheng","year":"2013","unstructured":"Sheng WQ, Huang D, Ying JM, Lu N, Wu HM, Liu YH, et al. HER2 status in gastric cancers: a retrospective analysis from four Chinese representative clinical centers and assessment of its prognostic significance. Ann Oncol. 2013;24(9):2360\u20134.","journal-title":"Ann Oncol"},{"issue":"11","key":"1804_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0080290","volume":"8","author":"D Huang","year":"2013","unstructured":"Huang D, Lu N, Fan Q, Sheng W, Bu H, Jin X, et al. HER2 status in gastric and gastroesophageal junction cancer assessed by local and central laboratories: Chinese results of the HER-EAGLE study. PLoS ONE. 2013;8(11):e80290.","journal-title":"PLoS ONE"},{"issue":"1","key":"1804_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-023-00731-1","volume":"14","author":"H Shimizu","year":"2023","unstructured":"Shimizu H, Kochi M, Fujii M, Watabe M, Matsuno Y, Kawai T, et al. Human epidermal growth factor 2 overexpressed alpha-fetoprotein-producing-gastric cancer. Discov Oncol. 2023;14(1):111.","journal-title":"Discov Oncol"},{"issue":"12","key":"1804_CR20","doi-asserted-by":"publisher","first-page":"e1303","DOI":"10.1634\/theoncologist.2018-0845","volume":"24","author":"J Subramanian","year":"2019","unstructured":"Subramanian J, Katta A, Masood A, Vudem DR, Kancha RK. Emergence of ERBB2 mutation as a biomarker and an actionable target in solid cancers. Oncologist. 2019;24(12):e1303\u201314.","journal-title":"Oncologist"},{"issue":"5","key":"1804_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000279","volume":"2","author":"CM Connell","year":"2017","unstructured":"Connell CM, Doherty GJ. Activating HER2 mutations as emerging targets in multiple solid cancers. ESMO Open. 2017;2(5):e000279.","journal-title":"ESMO Open"},{"issue":"4","key":"1804_CR22","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.ccell.2019.09.001","volume":"36","author":"JP Robichaux","year":"2019","unstructured":"Robichaux JP, Elamin YY, Vijayan RSK, Nilsson MB, Hu L, He J, et al. Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. Cancer Cell. 2019;36(4):444-57.e7.","journal-title":"Cancer Cell"},{"issue":"7691","key":"1804_CR23","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/nature25475","volume":"554","author":"DM Hyman","year":"2018","unstructured":"Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2018;554(7691):189\u201394.","journal-title":"Nature"},{"key":"1804_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.103074","volume":"62","author":"Z Li","year":"2020","unstructured":"Li Z, Chen S, Feng W, Luo Y, Lai H, Li Q, et al. A pan-cancer analysis of HER2 index revealed transcriptional pattern for precise selection of HER2-targeted therapy. EBioMedicine. 2020;62:103074.","journal-title":"EBioMedicine"},{"issue":"2","key":"1804_CR25","volume":"1876","author":"S Cen","year":"2021","unstructured":"Cen S, Liu Z, Pan H, Han W. Clinicopathologic features and treatment advances in cancers with HER2 alterations. Biochim Biophys Acta. 2021;1876(2):188605.","journal-title":"Biochim Biophys Acta"},{"issue":"7517","key":"1804_CR26","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"Cancer Genome Atlas Research Network","year":"2014","unstructured":"Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202\u20139.","journal-title":"Nature"},{"issue":"1","key":"1804_CR27","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1158\/1078-0432.CCR-05-0976","volume":"12","author":"JW Lee","year":"2006","unstructured":"Lee JW, Soung YH, Seo SH, Kim SY, Park CH, Wang YP, et al. Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. Clin Cancer Res. 2006;12(1):57\u201361.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1804_CR28","doi-asserted-by":"publisher","first-page":"105","DOI":"10.21873\/cgp.20307","volume":"19","author":"S Park","year":"2022","unstructured":"Park S, Ahn S, Kim DG, Kim H, Kang SY, Kim KM. High frequency of juxtamembrane domain ERBB2 mutation in gastric cancer. Cancer Genomics Proteomics. 2022;19(1):105\u201312.","journal-title":"Cancer Genomics Proteomics"},{"issue":"32","key":"1804_CR29","doi-asserted-by":"publisher","first-page":"3932","DOI":"10.1200\/JCO.2012.43.1890","volume":"30","author":"HH Yoon","year":"2012","unstructured":"Yoon HH, Shi Q, Sukov WR, Lewis MA, Sattler CA, Wiktor AE, et al. Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma. J Clin Oncol. 2012;30(32):3932\u20138.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1804_CR30","first-page":"1417","volume":"12","author":"S Wang","year":"2011","unstructured":"Wang S, Zheng G, Chen L, Xiong B. Effect of HER-2\/neu over-expression on prognosis in gastric cancer: a meta-analysis. Asian Pac J Cancer Prev. 2011;12(6):1417\u201323.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"6","key":"1804_CR31","first-page":"943","volume":"2","author":"SD Xie","year":"2009","unstructured":"Xie SD, Xu CY, Shen JG, Jiang ZN, Shen JY, Wang LB. HER 2\/neu protein expression in gastric cancer is associated with poor survival. Mol Med Rep. 2009;2(6):943\u20136.","journal-title":"Mol Med Rep"},{"key":"1804_CR32","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7150\/jca.4090","volume":"3","author":"JT J\u00f8rgensen","year":"2012","unstructured":"J\u00f8rgensen JT, Hersom M. HER2 as a prognostic marker in gastric cancer - a systematic analysis of data from the literature. J Cancer. 2012;3:137\u201344.","journal-title":"J Cancer"},{"issue":"1","key":"1804_CR33","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s10120-013-0239-9","volume":"17","author":"M Aizawa","year":"2014","unstructured":"Aizawa M, Nagatsuma AK, Kitada K, Kuwata T, Fujii S, Kinoshita T, et al. Evaluation of HER2-based biology in 1,006 cases of gastric cancer in a Japanese population. Gastric Cancer. 2014;17(1):34\u201342.","journal-title":"Gastric Cancer"},{"key":"1804_CR34","doi-asserted-by":"publisher","first-page":"1750329","DOI":"10.1155\/2019\/1750329","volume":"2019","author":"Y Liu","year":"2019","unstructured":"Liu Y, Yang M, Jiang T, Lan C, Yuan H, Li G, et al. Quantitative analysis of HER2 amplification by droplet digital PCR in the follow-up of gastric cancer patients being treated with trastuzumab after surgery. Gastroenterology Research and Practice. 2019;2019:1750329.","journal-title":"Gastroenterology Research and Practice"},{"issue":"10","key":"1804_CR35","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.3390\/jcm10102108","volume":"10","author":"CG Lengyel","year":"2021","unstructured":"Lengyel CG, Hussain S, Trapani D, El Bairi K, Altuna SC, Seeber A, et al. The Emerging Role of Liquid Biopsy in Gastric Cancer. J Clin Med. 2021;10(10):2108.","journal-title":"J Clin Med"},{"key":"1804_CR36","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.ebiom.2019.04.003","volume":"43","author":"Y Wang","year":"2019","unstructured":"Wang Y, Zhao C, Chang L, Jia R, Liu R, Zhang Y, et al. Circulating tumor DNA analyses predict progressive disease and indicate trastuzumab-resistant mechanism in advanced gastric cancer. EBioMedicine. 2019;43:261\u20139.","journal-title":"EBioMedicine"},{"issue":"10","key":"1804_CR37","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41419-019-1907-4","volume":"10","author":"Z Chen","year":"2019","unstructured":"Chen Z, Zhang C, Zhang M, Li B, Niu Y, Chen L, et al. Chromosomal instability of circulating tumor DNA reflect therapeutic responses in advanced gastric cancer. Cell Death Dis. 2019;10(10):697.","journal-title":"Cell Death Dis"},{"issue":"7","key":"1804_CR38","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1136\/gutjnl-2018-316522","volume":"68","author":"DS Wang","year":"2019","unstructured":"Wang DS, Liu ZX, Lu YX, Bao H, Wu X, Zeng ZL, et al. Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer. Gut. 2019;68(7):1152\u201361.","journal-title":"Gut"},{"issue":"5","key":"1804_CR39","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/s41591-019-0380-z","volume":"25","author":"DG Rothwell","year":"2019","unstructured":"Rothwell DG, Ayub M, Cook N, Thistlethwaite F, Carter L, Dean E, et al. Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study. Nat Med. 2019;25(5):738\u201343.","journal-title":"Nat Med"},{"key":"1804_CR40","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ejca.2017.10.032","volume":"88","author":"H Wang","year":"2018","unstructured":"Wang H, Li B, Liu Z, Gong J, Shao L, Ren J, et al. HER2 copy number of circulating tumour DNA functions as a biomarker to predict and monitor trastuzumab efficacy in advanced gastric cancer. European J Cancer. 2018;88:92\u2013100.","journal-title":"European J Cancer"},{"issue":"8","key":"1804_CR41","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.254","volume":"10","author":"C Zhang","year":"2020","unstructured":"Zhang C, Chen Z, Chong X, Chen Y, Wang Z, Yu R, et al. Clinical implications of plasma ctDNA features and dynamics in gastric cancer treated with HER2-targeted therapies. Clin Transl Med. 2020;10(8):e254.","journal-title":"Clin Transl Med"},{"issue":"4","key":"1804_CR42","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1093\/annonc\/mdy034","volume":"29","author":"ST Kim","year":"2018","unstructured":"Kim ST, Banks KC, Pectasides E, Kim SY, Kim K, Lanman RB, et al. Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients. Ann Oncol. 2018;29(4):1037\u201348.","journal-title":"Ann Oncol"},{"issue":"32","key":"1804_CR43","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.1200\/JCO.23.02626","volume":"42","author":"M Yagisawa","year":"2024","unstructured":"Yagisawa M, Taniguchi H, Satoh T, Kadowaki S, Sunakawa Y, Nishina T, et al. Trastuzumab deruxtecan in advanced solid tumors with human epidermal growth factor receptor 2 amplification identified by plasma cell-free DNA testing: a multicenter, single-arm, phase ii basket trial. J Clin Oncol. 2024;42(32):3817\u201325.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1804_CR44","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1111\/cas.13314","volume":"108","author":"J Gao","year":"2017","unstructured":"Gao J, Wang H, Zang W, Li B, Rao G, Li L, et al. Circulating tumor DNA functions as an alternative for tissue to overcome tumor heterogeneity in advanced gastric cancer. Cancer Sci. 2017;108(9):1881\u20137.","journal-title":"Cancer Sci"},{"issue":"2","key":"1804_CR45","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3892\/mco.2017.1125","volume":"6","author":"Y Liu","year":"2017","unstructured":"Liu Y, Ling Y, Qi Q, Lan F, Zhu M, Zhang Y, et al. Prognostic value of circulating tumor cells in advanced gastric cancer patients receiving chemotherapy. Mol Clin Oncol. 2017;6(2):235\u201342.","journal-title":"Mol Clin Oncol"},{"issue":"3","key":"1804_CR46","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3343\/alm.2023.0389","volume":"44","author":"JS Lee","year":"2024","unstructured":"Lee JS, Cho EH, Kim B, Hong J, Kim YG, Kim Y, et al. Clinical practice guideline for blood-based circulating tumor DNA assays. Ann Lab Med. 2024;44(3):195\u2013209.","journal-title":"Ann Lab Med"},{"issue":"2","key":"1804_CR47","doi-asserted-by":"publisher","first-page":"351","DOI":"10.4143\/crt.2022.1026","volume":"55","author":"H Kim","year":"2023","unstructured":"Kim H, Park KU. Clinical circulating tumor DNA testing for precision oncology. Cancer Res Treat. 2023;55(2):351\u201366.","journal-title":"Cancer Res Treat"},{"issue":"8","key":"1804_CR48","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","volume":"33","author":"J Pascual","year":"2022","unstructured":"Pascual J, Attard G, Bidard FC, Curigliano G, De Mattos-Arruda L, Diehn M, et al. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2022;33(8):750\u201368.","journal-title":"Ann Oncol"},{"issue":"5","key":"1804_CR49","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/modpathol.2011.198","volume":"25","author":"J R\u00fcschoff","year":"2012","unstructured":"R\u00fcschoff J, Hanna W, Bilous M, Hofmann M, Osamura RY, Penault-Llorca F, et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol. 2012;25(5):637\u201350.","journal-title":"Mod Pathol"},{"issue":"18_suppl","key":"1804_CR50","doi-asserted-by":"publisher","first-page":"13118","DOI":"10.1200\/jco.2006.24.18_suppl.13118","volume":"24","author":"T Prempree","year":"2006","unstructured":"Prempree T, Wongpaksa C. Mutations of HER2 gene in HER2-positive metastatic breast cancer. J Clin Oncol. 2006;24(18_suppl):13118.","journal-title":"J Clin Oncol"},{"key":"1804_CR51","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s12967-015-0476-2","volume":"13","author":"DH Yu","year":"2015","unstructured":"Yu DH, Tang L, Dong H, Dong Z, Zhang L, Fu J, et al. Oncogenic HER2 fusions in gastric cancer. J Transl Med. 2015;13:116.","journal-title":"J Transl Med"},{"issue":"3","key":"1804_CR52","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/sj.bjc.6604885","volume":"100","author":"JD Barros-Silva","year":"2009","unstructured":"Barros-Silva JD, Leit\u00e3o D, Afonso L, Vieira J, Dinis-Ribeiro M, Fragoso M, et al. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer. 2009;100(3):487\u201393.","journal-title":"Br J Cancer"},{"issue":"6","key":"1804_CR53","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.humpath.2015.02.011","volume":"46","author":"X Ge","year":"2015","unstructured":"Ge X, Wang H, Zeng H, Jin X, Sujie A, Xu C, et al. Clinical significance of assessing Her2\/neu expression in gastric cancer with dual tumor tissue paraffin blocks. Hum Pathol. 2015;46(6):850\u20137.","journal-title":"Hum Pathol"},{"issue":"9","key":"1804_CR54","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1158\/1078-0432.CCR-10-2203","volume":"17","author":"MA Shah","year":"2011","unstructured":"Shah MA, Khanin R, Tang L, Janjigian YY, Klimstra DS, Gerdes H, et al. Molecular classification of gastric cancer: a new paradigm. Clin Cancer Res. 2011;17(9):2693\u2013701.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1804_CR55","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.trecan.2023.11.001","volume":"10","author":"C Valenza","year":"2024","unstructured":"Valenza C, Guidi L, Battaiotto E, Trapani D, Sartore Bianchi A, Siena S, et al. Targeting HER2 heterogeneity in breast and gastrointestinal cancers. Trends in cancer. 2024;10(2):113\u201323.","journal-title":"Trends in cancer"},{"issue":"4","key":"1804_CR56","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s10120-021-01182-9","volume":"24","author":"G Roviello","year":"2021","unstructured":"Roviello G, Aprile G, D\u2019Angelo A, Iannone LF, Roviello F, Polom K, et al. Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: where do we stand? Gastric Cancer. 2021;24(4):765\u201379.","journal-title":"Gastric Cancer"},{"issue":"2","key":"1804_CR57","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s10120-015-0502-3","volume":"19","author":"N Tominaga","year":"2016","unstructured":"Tominaga N, Gotoda T, Hara M, Hale MD, Tsuchiya T, Matsubayashi J, et al. Five biopsy specimens from the proximal part of the tumor reliably determine HER2 protein expression status in gastric cancer. Gastric Cancer. 2016;19(2):553\u201360.","journal-title":"Gastric Cancer"},{"issue":"1","key":"1804_CR58","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1007\/s10120-014-0453-0","volume":"19","author":"SC Huang","year":"2016","unstructured":"Huang SC, Ng KF, Lee SE, Chen KH, Yeh TS, Chen TC. HER2 testing in paired biopsy and excision specimens of gastric cancer: the reliability of the scoring system and the clinicopathological factors relevant to discordance. Gastric Cancer. 2016;19(1):176\u201382.","journal-title":"Gastric Cancer"},{"issue":"2","key":"1804_CR59","doi-asserted-by":"publisher","first-page":"E165","DOI":"10.1055\/s-0034-1391359","volume":"3","author":"I Gullo","year":"2015","unstructured":"Gullo I, Grillo F, Molinaro L, Fassan M, De Silvestri A, Tinelli C, et al. Minimum biopsy set for HER2 evaluation in gastric and gastro-esophageal junction cancer. Endosc Int Open. 2015;3(2):E165\u201370.","journal-title":"Endosc Int Open"},{"issue":"6","key":"1804_CR60","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/modpathol.2012.228","volume":"26","author":"N Fusco","year":"2013","unstructured":"Fusco N, Rocco EG, Del Conte C, Pellegrini C, Bulfamante G, Di Nuovo F, et al. HER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions. Mod Pathol. 2013;26(6):816\u201324.","journal-title":"Mod Pathol"},{"issue":"4","key":"1804_CR61","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/ajco.12263","volume":"10","author":"KM Kim","year":"2014","unstructured":"Kim KM, Bilous M, Chu KM, Kim BS, Kim WH, Park YS, et al. Human epidermal growth factor receptor 2 testing in gastric cancer: recommendations of an Asia-Pacific task force. Asia Pac J Clin Oncol. 2014;10(4):297\u2013307.","journal-title":"Asia Pac J Clin Oncol"},{"issue":"3","key":"1804_CR62","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s10120-018-0891-1","volume":"22","author":"S Seo","year":"2019","unstructured":"Seo S, Ryu MH, Park YS, Ahn JY, Park Y, Park SR, et al. Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3). Gastric Cancer. 2019;22(3):527\u201335.","journal-title":"Gastric Cancer"},{"issue":"5","key":"1804_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100563","volume":"7","author":"DVT Catenacci","year":"2022","unstructured":"Catenacci DVT, Kang YK, Yoon HH, Shim BY, Kim ST, Oh DY, et al. Margetuximab with Retifanlimab as first-line therapy in HER2+\/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A. ESMO Open. 2022;7(5):100563.","journal-title":"ESMO Open"},{"issue":"5","key":"1804_CR64","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s40265-021-01485-2","volume":"81","author":"A Markham","year":"2021","unstructured":"Markham A. Margetuximab: first approval. Drugs. 2021;81(5):599\u2013604.","journal-title":"Drugs"},{"issue":"1","key":"1804_CR65","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","volume":"17","author":"DY Oh","year":"2020","unstructured":"Oh DY, Bang YJ. HER2-targeted therapies - a role beyond breast cancer. Nat Rev Clin Oncol. 2020;17(1):33\u201348.","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"1804_CR66","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1016\/S1470-2045(18)30481-9","volume":"19","author":"J Tabernero","year":"2018","unstructured":"Tabernero J, Hoff PM, Shen L, Ohtsu A, Shah MA, Cheng K, et al. Pertuzumab plus Trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2018;19(10):1372\u201384.","journal-title":"Lancet Oncol"},{"issue":"20","key":"1804_CR67","doi-asserted-by":"publisher","first-page":"6437","DOI":"10.1158\/1078-0432.CCR-11-0762","volume":"17","author":"PM LoRusso","year":"2011","unstructured":"LoRusso PM, Weiss D, Guardino E, Girish S, Sliwkowski MX. Trastuzumab Emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res. 2011;17(20):6437\u201347.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1804_CR68","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1080\/10717544.2019.1704942","volume":"27","author":"X Yu","year":"2020","unstructured":"Yu X, Wu H, Hu H, Dong Z, Dang Y, Qi Q, et al. Zein nanoparticles as nontoxic delivery system for maytansine in the treatment of non-small cell lung cancer. Drug Delivery. 2020;27(1):100\u20139.","journal-title":"Drug Delivery"},{"issue":"7","key":"1804_CR69","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","volume":"380","author":"G von Minckwitz","year":"2019","unstructured":"von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab Emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617\u201328.","journal-title":"N Engl J Med"},{"issue":"7","key":"1804_CR70","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","volume":"382","author":"S Modi","year":"2020","unstructured":"Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382(7):610\u201321.","journal-title":"N Engl J Med"},{"issue":"7","key":"1804_CR71","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S1470-2045(14)70178-0","volume":"15","author":"IE Krop","year":"2014","unstructured":"Krop IE, Kim SB, Gonz\u00e1lez-Mart\u00edn A, LoRusso PM, Ferrero JM, Smitt M, et al. Trastuzumab emtansine versus treatment of physician\u2019s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(7):689\u201399.","journal-title":"Lancet Oncol"},{"issue":"5","key":"1804_CR72","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/S1470-2045(17)30111-0","volume":"18","author":"PC Thuss-Patience","year":"2017","unstructured":"Thuss-Patience PC, Shah MA, Ohtsu A, Van Cutsem E, Ajani JA, Castro H, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2\/3 study. Lancet Oncol. 2017;18(5):640\u201353.","journal-title":"Lancet Oncol"},{"key":"1804_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.111682","volume":"183","author":"Z Xu","year":"2019","unstructured":"Xu Z, Guo D, Jiang Z, Tong R, Jiang P, Bai L, et al. Novel HER2-targeting antibody-drug conjugates of trastuzumab beyond T-DM1 in breast cancer: trastuzumab deruxtecan (DS-8201a) and (Vic-) trastuzumab duocarmazine (SYD985). Eur J Med Chem. 2019;183:111682.","journal-title":"Eur J Med Chem"},{"key":"1804_CR74","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.annonc.2020.04.064","volume":"31","author":"K Yamaguchi","year":"2020","unstructured":"Yamaguchi K, Bang Y, Iwasa S, Sugimoto N, Ryu M, Sakai D, et al. O-11 Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma: A randomized, phase 2, multicenter, open-label study (DESTINY-Gastric01). Ann Oncol. 2020;31:235.","journal-title":"Ann Oncol"},{"key":"1804_CR75","doi-asserted-by":"crossref","unstructured":"Gauzy-Lazo L, Sassoon I, Brun MP. Advances in Antibody-Drug Conjugate Design: Current Clinical Landscape and Future Innovations. SLAS discovery : advancing life sciences R & D. 2020;25(8):843-68.","DOI":"10.1177\/2472555220912955"},{"issue":"6","key":"1804_CR76","doi-asserted-by":"publisher","first-page":"737","DOI":"10.3390\/cancers11060737","volume":"11","author":"DM Collins","year":"2019","unstructured":"Zhu K, Yang X, Tai H, Zhong X, Luo T, Zheng H. HER2-targeted therapies in cancer: a systematic review. Biomark Res. 2024 Feb 2;12(1):16.","journal-title":"Cancers"},{"key":"1804_CR77","unstructured":"1523P Phase II dose optimization results from MOUNTAINEER-02: A study of tucatinib, trastuzumab, ramucirumab, and paclitaxel for HER2+ gastroesophageal cancer (GEC) (annalsofoncology.org)"},{"key":"1804_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105379","volume":"109","author":"S Liu","year":"2024","unstructured":"Liu S, Lan B, Wang Y, Yang T, Li L, Ge H, et al. Pyrotinib and trastuzumab combination treatment synergistically overcomes HER2 dependency in HER2-positive breast cancer: insights from the PHILA trial. EBioMedicine. 2024;109:105379.","journal-title":"EBioMedicine"},{"issue":"1","key":"1804_CR79","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1038\/s41467-023-37029-3","volume":"14","author":"NE Weisser","year":"2023","unstructured":"Weisser NE, Sanches M, Escobar-Cabrera E, O\u2019Toole J, Whalen E, Chan PWY, et al. An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity. Nat Commun. 2023;14(1):1394.","journal-title":"Nat Commun"},{"key":"1804_CR80","unstructured":"Jianming Xu et al. KN026 in combination with chemotherapy for previously treated HER2-positive gastric or gastroesophageal carcinomas (GC\/GEJC): Interim analysis of KC-WISE. 2025 ESMO, LBA78."},{"key":"1804_CR81","doi-asserted-by":"crossref","unstructured":"Elena Elimova et al. Zanidatamab + chemotherapy \u00b1 tislelizumab for first-line HER2-positive locally advanced, unresectable, or metastatic gastroesophageal adenocarcinoma: Primary analysis from HERIZON-GEA-01. 2026 ASCO.","DOI":"10.1200\/JCO.2026.44.2_suppl.LBA285"},{"issue":"9","key":"1804_CR82","first-page":"3037","volume":"10","author":"F Wang","year":"2020","unstructured":"Wang F, Liu TS, Yuan XL, Luo HY, Gu KS, Yuan Y, et al. Trastuzumab plus docetaxel and capecitabine as a first-line treatment for HER2-positive advanced gastric or gastroesophageal junction cancer: a phase II, multicenter, open-label, single-arm study. Am J Cancer Res. 2020;10(9):3037\u201346.","journal-title":"Am J Cancer Res"},{"issue":"9","key":"1804_CR83","doi-asserted-by":"publisher","first-page":"e1567","DOI":"10.1002\/onco.13826","volume":"26","author":"S Qin","year":"2021","unstructured":"Qin S, Ji J, Xu RH, Wang W, Tang Y, Bi F, et al. Treatment patterns and outcomes in Chinese patients with gastric cancer by HER2 status: A noninterventional registry study (EVIDENCE). Oncologist. 2021;26(9):e1567\u201380.","journal-title":"Oncologist"},{"issue":"22","key":"1804_CR84","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1200\/JCO.2016.71.6852","volume":"35","author":"MA Shah","year":"2017","unstructured":"Shah MA, Xu RH, Bang YJ, Hoff PM, Liu T, Herr\u00e1ez-Baranda LA, et al. HELOISE: Phase IIIb randomized multicenter study comparing standard-of-care and higher-dose trastuzumab regimens combined with chemotherapy as first-line therapy in patients with human epidermal growth factor receptor 2-positive metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol. 2017;35(22):2558\u201367.","journal-title":"J Clin Oncol"},{"key":"1804_CR85","doi-asserted-by":"publisher","first-page":"S877","DOI":"10.1016\/j.annonc.2024.08.1466","volume":"35","author":"YY Janjigian","year":"2024","unstructured":"Janjigian YY, Kawazoe A, Bai Y, Xu J, Lonardi S, Metges JP, et al. 1400O Final overall survival for the phase III, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+ advanced, unresectable or metastatic G\/GEJ adenocarcinoma. Ann Oncol. 2024;35:S877\u20138.","journal-title":"Ann Oncol"},{"issue":"6","key":"1804_CR86","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/S1470-2045(20)30169-8","volume":"21","author":"YY Janjigian","year":"2020","unstructured":"Janjigian YY, Maron SB, Chatila WK, Millang B, Chavan SS, Alterman C, et al. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2020;21(6):821\u201331.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1804_CR87","doi-asserted-by":"publisher","first-page":"499","DOI":"10.21037\/jgo.2016.06.16","volume":"7","author":"HO Al-Shamsi","year":"2016","unstructured":"Al-Shamsi HO, Fahmawi Y, Dahbour I, Tabash A, Rogers JE, Mares JE, et al. Continuation of trastuzumab beyond disease progression in HER2-positive metastatic gastric cancer: the MD Anderson experience. J Gastrointest Oncol. 2016;7(4):499\u2013505.","journal-title":"J Gastrointest Oncol"},{"issue":"17","key":"1804_CR88","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1200\/JCO.19.03077","volume":"38","author":"A Makiyama","year":"2020","unstructured":"Makiyama A, Sukawa Y, Kashiwada T, Kawada J, Hosokawa A, Horie Y, et al. Randomized, phase II study of trastuzumab beyond progression in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: WJOG7112G (T-ACT Study). J Clin Oncol. 2020;38(17):1919\u201327.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1804_CR89","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1002\/ijc.30383","volume":"140","author":"K Nishikawa","year":"2017","unstructured":"Nishikawa K, Takahashi T, Takaishi H, Miki A, Noshiro H, Yoshikawa T, et al. Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane- and trastuzumab-na\u00efve patients with HER2-positive, previously treated, advanced, or recurrent gastric cancer (JFMC45-1102). Int J Cancer. 2017;140(1):188\u201396.","journal-title":"Int J Cancer"},{"issue":"27","key":"1804_CR90","doi-asserted-by":"publisher","first-page":"4394","DOI":"10.1200\/JCO.22.02122","volume":"41","author":"CG Kim","year":"2023","unstructured":"Kim CG, Jung M, Kim HS, Lee CK, Jeung HC, Koo DH, et al. Trastuzumab combined with ramucirumab and paclitaxel in patients with previously treated human epidermal growth factor receptor 2-positive advanced gastric or gastroesophageal junction cancer. J Clin Oncol. 2023;41(27):4394\u2013405.","journal-title":"J Clin Oncol"},{"key":"1804_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102415","volume":"68","author":"Y Wang","year":"2024","unstructured":"Wang Y, Gong J, Wang A, Wei J, Peng Z, Wang X, et al. Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial. EClinicalMedicine. 2024;68:102415.","journal-title":"EClinicalMedicine"},{"issue":"7","key":"1804_CR92","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/S1470-2045(23)00215-2","volume":"24","author":"E Van Cutsem","year":"2023","unstructured":"Van Cutsem E, di Bartolomeo M, Smyth E, Chau I, Park H, Siena S, et al. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a Trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. Lancet Oncol. 2023;24(7):744\u201356.","journal-title":"Lancet Oncol"},{"key":"1804_CR93","doi-asserted-by":"crossref","unstructured":"Shitara K, Gumus M, Pietrantonio F, Lonardi S, Fouchardiere CDL, Coutzac C, et al. Trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) + paclitaxel (PTX) in second-line treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) unresectable\/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary analysis of the randomized, phase 3 DESTINY-Gastric04 study. J Clin Oncol. 2025;43(17_suppl):LBA4002-LBA.","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA4002"},{"issue":"13","key":"1804_CR94","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1200\/JCO.2015.63.5995","volume":"34","author":"J Li","year":"2016","unstructured":"Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, et al. Randomized, double-blind, placebo-controlled phase III trial of Apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol. 2016;34(13):1448\u201354.","journal-title":"J Clin Oncol"},{"issue":"10111","key":"1804_CR95","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"YK Kang","year":"2017","unstructured":"Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England). 2017;390(10111):2461\u201371.","journal-title":"Lancet (London, England)"},{"key":"1804_CR96","doi-asserted-by":"publisher","first-page":"S1542","DOI":"10.1016\/j.annonc.2023.10.307","volume":"34","author":"L Shen","year":"2023","unstructured":"Shen L, Chen P, Lu J, Wan Y, Zheng Y, Ye F, et al. 172P Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced\/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): primary efficacy and safety from the phase II single-arm DESTINY-Gastric06 (DG06) trial. Ann Oncol. 2023;34:S1542\u20133.","journal-title":"Ann Oncol"},{"issue":"9","key":"1804_CR97","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1002\/(SICI)1097-0142(19990501)85:9<1894::AID-CNCR3>3.0.CO;2-J","volume":"85","author":"M Nakajima","year":"1999","unstructured":"Nakajima M, Sawada H, Yamada Y, Watanabe A, Tatsumi M, Yamashita J, et al. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer. 1999;85(9):1894\u2013902.","journal-title":"Cancer"},{"issue":"1","key":"1804_CR98","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s00432-019-03060-5","volume":"146","author":"Q Li","year":"2020","unstructured":"Li Q, Lv M, Jiang H, Wang Y, Yu S, Li W, et al. A prospective observational study on the optimal maintenance strategy in HER2-positive advanced gastric cancer treated with trastuzumab-based therapy. J Cancer Res Clin Oncol. 2020;146(1):287\u201395.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"1804_CR99","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s10120-023-01374-5","volume":"26","author":"ES Bergen","year":"2023","unstructured":"Bergen ES, Pilla L, Auclin E, Ilhan-Mutlu A, Prager GW, Pietrantonio F, et al. Optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma-a retrospective, international, multicentric AGEO study. Gastric Cancer. 2023;26(3):425\u201337.","journal-title":"Gastric Cancer"},{"issue":"2","key":"1804_CR100","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1007\/s12029-021-00594-1","volume":"53","author":"M G\u00fcrb\u00fcz","year":"2022","unstructured":"G\u00fcrb\u00fcz M, Akku\u015f E, Sakin A, Urvay S, Demiray AG, \u015eahin S, et al. Trastuzumab \u00b1 Capecitabine maintenance after the first-line treatment of HER2-positive advanced gastric cancer: retrospective observational real-life data of Turkish Oncology Group. J Gastrointest Cancer. 2022;53(2):282\u20138.","journal-title":"J Gastrointest Cancer"},{"issue":"10418","key":"1804_CR101","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","volume":"402","author":"YY Janjigian","year":"2023","unstructured":"Janjigian YY, Kawazoe A, Bai Y, Xu J, Lonardi S, Metges JP, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet (London, England). 2023;402(10418):2197\u2013208.","journal-title":"Lancet (London, England)"},{"issue":"1","key":"1804_CR102","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1158\/2159-8290.CD-17-0395","volume":"8","author":"E Pectasides","year":"2018","unstructured":"Pectasides E, Stachler MD, Derks S, Liu Y, Maron S, Islam M, et al. Genomic heterogeneity as a barrier to precision medicine in gastroesophageal adenocarcinoma. Cancer Discov. 2018;8(1):37\u201348.","journal-title":"Cancer Discov"},{"issue":"7126","key":"1804_CR103","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nature05474","volume":"445","author":"NV Sergina","year":"2007","unstructured":"Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature. 2007;445(7126):437\u201341.","journal-title":"Nature"},{"issue":"13","key":"1804_CR104","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1200\/JCO.20.02761","volume":"39","author":"I Haffner","year":"2021","unstructured":"Haffner I, Schierle K, Raim\u00fandez E, Geier B, Maier D, Hasenauer J, et al. HER2 expression, test deviations, and their impact on survival in metastatic gastric cancer: results from the prospective multicenter VARIANZ study. J Clin Oncol. 2021;39(13):1468\u201378.","journal-title":"J Clin Oncol"},{"issue":"23","key":"1804_CR105","doi-asserted-by":"publisher","first-page":"7098","DOI":"10.1158\/1078-0432.CCR-19-1704","volume":"25","author":"SB Maron","year":"2019","unstructured":"Maron SB, Chase LM, Lomnicki S, Kochanny S, Moore KL, Joshi SS, et al. Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma. Clin Cancer Res. 2019;25(23):7098\u2013112.","journal-title":"Clin Cancer Res"},{"key":"1804_CR106","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2024.42.3","author":"Z Peng","year":"2024","unstructured":"Peng Z, Zhang X, Liang H, Zheng Z, Wang Z, Liu H, et al. Atezolizumab and trastuzumab plus chemotherapy in patients with HER2+ locally advanced resectable gastric cancer or adenocarcinoma of the gastroesophageal junction: a multicenter, randomized, open-label phase II study. J Clin Oncol. 2024. https:\/\/doi.org\/10.1200\/jco.2024.42.3.","journal-title":"J Clin Oncol"},{"key":"1804_CR107","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.ejca.2020.12.005","volume":"145","author":"F Rivera","year":"2021","unstructured":"Rivera F, Izquierdo-Manuel M, Garc\u00eda-Alfonso P, Mart\u00ednez de Castro E, Gallego J, Lim\u00f3n ML, et al. Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial. Eur J Cancer. 2021;145:158\u201367.","journal-title":"Eur J Cancer"},{"issue":"6","key":"1804_CR108","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1002\/ijc.33696","volume":"149","author":"RD Hofheinz","year":"2021","unstructured":"Hofheinz RD, Hegewisch-Becker S, Kunzmann V, Thuss-Patience P, Fuchs M, Homann N, et al. Trastuzumab in combination with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2-positive locally advanced esophagogastric adenocarcinoma: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group. Int J Cancer. 2021;149(6):1322\u201331.","journal-title":"Int J Cancer"},{"issue":"15_suppl","key":"1804_CR109","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.4502","volume":"38","author":"RD Hofheinz","year":"2020","unstructured":"Hofheinz RD, Haag GM, Ettrich TJ, Borchert K, Kretzschmar A, Teschendorf C, et al. Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2-positive resectable esophagogastric adenocarcinoma: final results of the PETRARCA multicenter randomized phase II trial of the AIO. J Clin Oncol. 2020;38(15_suppl):4502-.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1804_CR110","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1007\/s10120-024-01467-9","volume":"27","author":"M Tokunaga","year":"2024","unstructured":"Tokunaga M, Machida N, Mizusawa J, Ito S, Yabusaki H, Hirao M, et al. Early endpoints of a randomized phase II trial of preoperative chemotherapy with S-1\/CDDP with or without trastuzumab followed by surgery for HER2-positive resectable gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301C (Trigger Study). Gastric Cancer. 2024;27(3):580\u20139.","journal-title":"Gastric Cancer"},{"issue":"8","key":"1804_CR111","doi-asserted-by":"publisher","first-page":"4413","DOI":"10.1245\/s10434-020-09405-6","volume":"28","author":"Q He","year":"2021","unstructured":"He Q, Chen J, Zhou K, Jin C, Wang A, Ji K, et al. Effect of additional trastuzumab in neoadjuvant and adjuvant treatment for patients with resectable HER2-positive gastric cancer. Ann Surg Oncol. 2021;28(8):4413\u201322.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"1804_CR112","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S1470-2045(21)00718-X","volume":"23","author":"HP Safran","year":"2022","unstructured":"Safran HP, Winter K, Ilson DH, Wigle D, DiPetrillo T, Haddock MG, et al. Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology\/RTOG 1010): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2022;23(2):259\u201369.","journal-title":"Lancet Oncol"},{"issue":"16_suppl","key":"1804_CR113","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.4057","volume":"41","author":"AD Wagner","year":"2023","unstructured":"Wagner AD, Grabsch HI, Mauer M, Fumagalli Romario U, Kang Y-K, Bouche O, et al. Integration of trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy (CT) of HER-2 positive gastric (GC) and esophagogastric junction cancer (EGJC): first results of the EORTC 1203 INNOVATION study, in collaboration with the Korean Cancer Study Group, and the Dutch Upper GI Cancer Group. J Clin Oncol. 2023;41(16_suppl):4057-.","journal-title":"J Clin Oncol"},{"key":"1804_CR114","doi-asserted-by":"publisher","first-page":"S908","DOI":"10.1016\/j.annonc.2024.08.1532","volume":"35","author":"F Wang","year":"2024","unstructured":"Wang F, Zhao C, Xia J, Liu Z, Meng X, Shan Z, et al. 1466P Efficacy and safety of perioperative chemotherapy combined with tislelizumab and trastuzumab for HER2-positive resectable gastric\/gastroesophageal junction cancer (GC\/EGJC): Data update from a phase II single-arm study. Ann Oncol. 2024;35:S908.","journal-title":"Ann Oncol"},{"issue":"7","key":"1804_CR115","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1097\/COC.0000000000000825","volume":"44","author":"H Abali","year":"2021","unstructured":"Abali H, Yalcin S, Onal HC, Dane F, Oksuzoglu B, Ozdemir N, et al. A phase II study of the combination of oxaliplatin, capecitabine, and trastuzumab and chemoradiotherapy in the adjuvant setting in operated patients with HER2-positive gastric or gastroesophageal junction cancer (TOXAG Study): A Turkish oncology group study. Am J Clin Oncol. 2021;44(7):301\u20137.","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"1804_CR116","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s10120-015-0575-z","volume":"19","author":"K Yoshida","year":"2016","unstructured":"Yoshida K, Yamaguchi K, Okumura N, Tanahashi T, Kodera Y. Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification. Gastric Cancer. 2016;19(2):329\u201338.","journal-title":"Gastric Cancer"},{"issue":"1","key":"1804_CR117","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-022-01331-8","volume":"26","author":"Japanese Gastric Cancer A","year":"2023","unstructured":"Japanese Gastric Cancer A. Japanese gastric cancer treatment guidelines 2021 (6th edition). Gastric Cancer. 2023;26(1):1\u201325.","journal-title":"Gastric Cancer"},{"issue":"2","key":"1804_CR118","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s00280-015-2807-7","volume":"76","author":"Y Mitsui","year":"2015","unstructured":"Mitsui Y, Sato Y, Miyamoto H, Fujino Y, Takaoka T, Miyoshi J, et al. Trastuzumab in combination with docetaxel\/cisplatin\/S-1 (DCS) for patients with HER2-positive metastatic gastric cancer: feasibility and preliminary efficacy. Cancer Chemother Pharmacol. 2015;76(2):375\u201382.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"12","key":"1804_CR119","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1007\/s00595-022-02515-6","volume":"52","author":"T Arigami","year":"2022","unstructured":"Arigami T, Matsushita D, Okubo K, Shimonosono M, Sasaki K, Tsuruda Y, et al. A prognostic scoring system for conversion surgery after trastuzumab-based chemotherapy for human epidermal growth factor receptor 2-positive advanced gastric cancer. Surg Today. 2022;52(12):1721\u201330.","journal-title":"Surg Today"},{"issue":"37","key":"1804_CR120","doi-asserted-by":"publisher","first-page":"61837","DOI":"10.18632\/oncotarget.18700","volume":"8","author":"J Soo Park","year":"2017","unstructured":"Soo Park J, Youn JC, Shim CY, Hong GR, Lee CK, Kim JH, et al. Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer. Oncotarget. 2017;8(37):61837\u201345.","journal-title":"Oncotarget"},{"issue":"41","key":"1804_CR121","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, Lopez-Fernandez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229\u2013361.","journal-title":"Eur Heart J"},{"key":"1804_CR122","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/103792s5354lbl.pdf."},{"key":"1804_CR123","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761139s032s035lbl.pdf."},{"key":"1804_CR124","unstructured":"https:\/\/www.enhertu.co.uk\/content\/dam\/intelligentcontent\/brands\/enhertu\/gb\/en\/enhertu-pdfs\/ENHERTU-ILD-UK-BCG-guideline-leave-piece.pdf."},{"issue":"4","key":"1804_CR125","first-page":"304","volume":"46","author":"Trastuzumab Deruxtecan Clinical Management P, Adverse Reaction Management Consensus Expert G","year":"2024","unstructured":"Trastuzumab Deruxtecan Clinical Management P, Adverse Reaction Management Consensus Expert G. Chinese expert consensus on the management of clinical pathway and adverse events of trastuzumab deruxtecan (2024 edition). Zhonghua Zhong Liu Za Zhi. 2024;46(4):304\u201318.","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"1804_CR126","unstructured":"https:\/\/www.adcreview.com\/wp-content\/uploads\/2022\/05\/Disitamab-vedotin-.pdf."}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-026-01804-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01804-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01804-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T17:04:29Z","timestamp":1782407069000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13045-026-01804-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":126,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1804"],"URL":"https:\/\/doi.org\/10.1186\/s13045-026-01804-8","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"assertion":[{"value":"2 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Declaration of interests Xiaotian Zhang reports receiving speaker fees from Daiichi Sankyo, AstraZeneca, Bristol Myers Squibb, MSD, BeiGene, Qilu, Hengrui, and Henlius. Fenghua Wang reports receiving speaker fees from Daiichi Sankyo, Bristol Myers Squibb, MSD, Astellas, and BeiGene, and consulting fees from Hengrui. Ruihua Xue reports receiving speaker fees from Daiichi Sankyo, Bristol Myers Squibb, Roche, Merck Serono, Hutchison, Hengrui, Junshi, Qilu, CPPC, and Henlius, and participation on advisory boards for Astellas, MSD, AstraZeneca, Junshi, Hengrui, BeiGene, Innovent, CPPC, and Keymed. Jin Li reports payments or honoraria for consulting or speaker bureaus from Daiichi Sankyo, ArteMed Hospital, Novartis, Hengrui, Boehringer Ingelheim, and Eli Lilly. Lin Shen reports consulting\/advisory roles with MSD, AstraZeneca, Boehringer Ingelheim, SERVIER, and Transcenta Holding Limited, speaker fees from Daiichi Sankyo, and institutional research funding from BeiGene. All other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"45"}}